Key information

🔎 Fund Overview

MEI Pharma, Inc. is a pharmaceutical company, which is engaged in developing cancer therapies. The Company’s pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor. Voruciclib has completed a Phase I trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) in combination with the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (marketed as Venclexta). Voruciclib is also being evaluated in pre-clinical studies to explore potential activity in various solid tumor cancers including in combination with therapies that target the RAS signaling pathway, such as KRAS inhibitors. CDK9 has functions in cell cycle regulation, including the modulation of two therapeutic targets in cancer: myeloid leukemia cell differentiation protein (MCL1) and the MYC proto-oncogene protein (MYC) which regulates cell proliferation and growth.